SCHEMBL832632

SCHEMBL832632

CCOC(=O)c1c(C(F)(F)F)nc(Cl)c(C)c1CC(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.39
ALDH1A1 P00352 7/20 0.37
POLB P06746 3/20 0.37
MAPK1 P28482 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HPGD P15428 3/20 0.36
GAA P10253 2/20 0.36
MAPT P10636 2/20 0.36
KMT2A Q03164 2/20 0.36
TP53 P04637 1/20 0.36
THRB P10828 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
LMNA P02545 4/20 0.35
PKM P14618 1/20 0.35
NPSR1 Q6W5P4 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MEN1 O00255 1/20 0.34
ATM Q13315 1/20 0.34
IDO1 P14902 1/20 0.34
RORC P51449 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6732478 0.87 KDM4E (0.44) KDM4EALDH1A1POLBMAPK1SMN1; SMN2
SCHEMBL829828 0.82 SMN1; SMN2 (0.41) KDM4EALDH1A1POLBSMN1; SMN2HPGD
SCHEMBL8359305 0.81 KDM4E (0.38) KDM4EALDH1A1POLBMAPK1SMN1; SMN2
SCHEMBL9189663 0.80 KDM4E (0.39) KDM4EALDH1A1POLBMAPK1SMN1; SMN2
SCHEMBL9726292 0.79 KDM4E (0.38) KDM4EALDH1A1POLBMAPK1SMN1; SMN2
SCHEMBL9589270 0.79 KDM4E (0.36) KDM4EALDH1A1POLBMAPK1SMN1; SMN2
SCHEMBL832501 0.77 ALDH1A1 (0.44) KDM4EALDH1A1POLBMAPK1SMN1; SMN2
SCHEMBL10579708 0.76 KDM4E (0.42) KDM4EALDH1A1POLBSMN1; SMN2HPGD
SCHEMBL9726294 0.76 KDM4E (0.36) KDM4EALDH1A1POLBMAPK1SMN1; SMN2
SCHEMBL9726378 0.75 KDM4E (0.48) KDM4EALDH1A1POLBSMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143411-B2 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2012-03-27 US disclosed
US-8143411-B2 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2012-03-27 US disclosed
US-8143411-B2 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2012-03-27 US disclosed
US-20100234432-A1 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2010-09-16 US disclosed
US-20100234432-A1 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2010-09-16 US disclosed
US-20100234432-A1 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2010-09-16 US disclosed
WO-2009033561-A1 SUBSTITUTED 6-PHEYLNICOTINIC ACIDS AND THE USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-03-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234432-A1 Substituted 6-phenylnicotinic acids and their use SLC5A6, FABP3, NAPRT KDM4E 3571/4885ALDH1A1 1238/4885POLB 3352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.